First batch of Sputnik V vaccine likely to reach Kanpur medical college for phase 2,3 trials by next week

As many as 180 volunteers have registered for the trials and the ethics committee of the college has also given permission, said college principal RB Kamal

Press Trust of India November 15, 2020 16:23:41 IST
First batch of Sputnik V vaccine likely to reach Kanpur medical college for phase 2,3 trials by next week

Representational image.

Kanpur: The first batch of Russia's Sputnik V vaccine for COVID-19 is likely to reach Kanpur's Ganesh Shankar Vidyarthi Medical College by next week, where the vaccine's Phase 2 and Phase 3 human clinical trials will be conducted.

The decision to conduct the human clinical trials of the vaccine was taken after Dr Reddy's Laboratories got approval from the Drugs Controller General of India (DCGI) in this regard, an official said.

Speaking to PTI, college principal RB Kamal said the human clinical trials of the vaccine will start from next week. "As many as 180 volunteers have registered for the trials. Head of the research, Saurabh Agarwal, will determine the dosage of the vaccine to be administered. One dose will be administered and the condition of volunteers will be monitored to determine whether they need further doses or not," he said.

Kamal said the volunteers' vitals and condition will be checked periodically and the data will be analysed to determine whether the vaccine is a success or not.

He said the effect of the vaccine on the volunteers will be studied for seven months after the same is administered once, twice or thrice within an interval of 21 days.

After observing the effects of the vaccine for a month, authorities will be apprised of the results of the trial and they will then make a decision accordingly. The ethics committee of the college has also given permission for the trials, he said.

The vaccine has to be kept at a temperature of -20 to -70 degrees Celsius.

In September, Dr Reddy's and the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, entered into a partnership to conduct clinical trials of the Sputnik V vaccine and its distribution in India.

As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr Reddy's upon regulatory approval in India.

On 11 August, the Sputnik V vaccine was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vector platform.

Updated Date:

also read

COVID-19 vaccine protects people of all body weights: Study
World

COVID-19 vaccine protects people of all body weights: Study

Vaccine effectiveness was similar for those with a higher body mass index and of a healthy weight, but slightly lower in the underweight group, who were also the least likely to have been vaccinated

India reports 16,135 new COVID-19 cases in last 24 hours; Kerala, Tamil Nadu, Maharashtra log most infections
India

India reports 16,135 new COVID-19 cases in last 24 hours; Kerala, Tamil Nadu, Maharashtra log most infections

The country now has 1,13,864 active cases of coronavirus. The active cases comprise 0.26 per cent of the total cases

India logs 17,070 new COVID-19 cases, 23 deaths in last 24 hours; active cases increase to 1,07,189
India

India logs 17,070 new COVID-19 cases, 23 deaths in last 24 hours; active cases increase to 1,07,189

The health ministry said that 14,413 patients recuperated from COVID-19 in the last 24 hours, increasing the total recoveries to 4,28,36,906